Ospemifeneのソースを表示

{{Short description|Selective estrogen receptor modulator}}
{{Drugbox
| IUPAC_name = 2-(''p''-((''Z'')-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)ethanol
| image = Ospemifene.svg
| width = 250
| alt = 

<!-- Clinical data -->
| tradename = Osphena, Senshio
| Drugs.com = 
| MedlinePlus = 
| DailyMedID = Ospemifene
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_category =
| routes_of_administration = [[Oral administration|By mouth]]
| class = [[Selective estrogen receptor modulator]]
| ATC_prefix = G03
| ATC_suffix = XC05

| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = Rx-only
| legal_CA_comment = <ref>{{Cite web |date=23 October 2014 |title=Summary Basis of Decision (SBD) for Osphena |url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00564&lang=en |access-date=29 May 2022 |website=Health Canada}}</ref><ref>{{Cite web |date=3 August 2022 |title=Health product highlights 2021: Annexes of products approved in 2021 |url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-product-highlights-2021/appendices.html |access-date=25 March 2024 |website=[[Health Canada]]}}</ref>
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = Rx-only
| legal_EU = Rx-only
| legal_status =

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number = 128607-22-7
| PubChem = 3036505
| DrugBank = DB04938
| ChemSpiderID = 2300501
| UNII = B0P231ILBK
| ChEMBL = 2105395
| ChEBI = 73275
| KEGG = D08958
| synonyms = Deaminohydroxytoremifene

<!-- Chemical data -->
| C=24 | H=23 | Cl=1 | O=2
| SMILES = OCCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1
| StdInChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-
| StdInChIKey = LUMKNAVTFCDUIE-VHXPQNKSSA-N
}}

'''Ospemifene''' (brand names '''Osphena''' and '''Senshio''' produced by [[Shionogi]]) is an oral medication indicated for the treatment of [[dyspareunia]]{{spaced ndash}}pain during sexual intercourse{{spaced ndash}}encountered by some women, more often in those who are [[menopause|post-menopausal]]. Ospemifene is a [[selective estrogen receptor modulator]] (SERM)<ref name="pmid14501605">{{Cite journal |vauthors=Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O |year=2003 |title=Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial |journal=Menopause |volume=10 |issue=5 |pages=433–9 |doi=10.1097/01.GME.0000063609.62485.27 |pmid=14501605 |s2cid=25481518}}</ref> acting similarly to an [[estrogen]] on the [[vaginal epithelium]], building vaginal wall thickness which in turn reduces the pain associated with dyspareunia. Dyspareunia is most commonly caused by "vulvar and vaginal atrophy."<ref name="test">{{Cite journal |last=Tanzi MG |date=April 2013 |title=Ospemifene: New treatment for postmenopausal women. |url=http://www.pharmacist.com/node/205934 |url-status=dead |journal=Pharmacy Today. American Pharmacists Association. |archive-url=https://web.archive.org/web/20171201043112/http://www.pharmacist.com/node/205934 |archive-date=2017-12-01 |access-date=2013-12-02}}</ref>

The medication was approved by the [[Food and Drug Administration|FDA]] in February 2013<ref>{{Cite news |date=2013-02-26 |title=FDA approves Osphena for postmenopausal women experiencing pain during sex |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm341128.htm |work=FDA News Release |publisher=U.S. Food and Drug Administration}}</ref> and by the European Commission for marketing in the EU in January 2015.<ref>{{Cite web |title=European Medicines Agency |url=http://www.ema.europa.eu/en/medicines/human/EPAR/senshio}}</ref>